The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
NIH to launch study of experimental monoclonal antibody therapy for COVID-19; a Q&A with the trial’s protocol chair: Davey Smith, MD, at UC San Diego School of Medicine
Researchers at University of California San Diego School of Medicine report that sleep may help people to learn continuously through their lifetime by encoding new memories and protecting old ones.
UC San Diego researchers discovered that people with an inactive RNA-editing enzyme respond better to cancer immunotherapy, and inhibitors of the enzyme help mice with difficult-to-treat cancers live longer.
People with inactive RNA-editing enzyme respond better to immunotherapy; inhibitors of the enzyme help mice with difficult-to-treat cancers live longer
Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers.
